Imjudo (tremelimumab) — “Turning up the Heat on Cancer: The Promise and Price of CTLA-4 Blockade”
Below is an in-depth, evidence-based article about Imjudo (active ingredient tremelimumab): who developed it, the intellectual-property picture, clinical benefits, limitations, and the main safety signals that emerged during trials and post-marketing. Key source material is the EMA EPAR/assessment report and major regulatory/clinical reviews (cited after the most important statements). Quick summary (TL;DR) Imjudo (tremelimumab) is […]
Nintedanib Accord: Europe’s First Generic Nintedanib—What to Know About Origins, Patents, Benefits, Risks, and Trial Safety
Short take: Nintedanib Accord is the EU-authorised generic of Boehringer Ingelheim’s nintedanib (brand: Ofev). It slows lung-function decline across several fibrosing interstitial lung diseases (ILDs). Its biggest upsides are consistent efficacy across IPF, progressive-phenotype ILDs, and SSc-ILD, plus an oral regimen and now a lower-cost generic option. The trade-offs are predictable: frequent GI side-effects (especially […]
Keytruda (pembrolizumab): a deep-dive
What it is. Keytruda is Merck & Co.’s (MSD outside the US/Canada) humanized IgG4 monoclonal antibody that blocks PD-1, releasing an immune “brake” so T-cells can attack cancer. In the EU it’s authorized—alone and in combinations—across a very broad slate of tumors (NSCLC, melanoma, RCC, urothelial, HNSCC, MSI-H/dMMR cancers, gastric/GEJ, oesophageal, cervical, TNBC, biliary tract, […]
Sixmo – A Long-Acting Implant for Opioid Dependence
What Is Sixmo? Sixmo is a buprenorphine hydrochloride implant designed as a long-lasting substitution treatment for opioid dependence. It is intended for clinically stable adult patients requiring a daily dose of no more than 8 mg of sublingual buprenorphine. The implant must be used alongside comprehensive medical, social, and psychological support.European Medicines Agency (EMA)European Pharmaceutical […]
Fluenz Tetra live attenuated quadrivalent influenza vaccine— A Comprehensive Overview
What Is Fluenz Tetra? Fluenz Tetra is a live attenuated quadrivalent influenza vaccine, administered intranasally as a needle-free spray. It protects against four influenza virus strains—two A types (H1N1 and H3N2) and two B types. This broader formulation offers enhanced protection compared to traditional trivalent vaccines.MedPath+1Wikipedia Originally approved by the European Commission on 4 December […]
EMA Confirms Suicidal Thoughts with Finasteride — Detailed summary, implications, and a practical pharmacovigilance / manufacturer action plan
Source documents: EMA PRAC communications and referral page (May–June 2025). European Medicines Agency (EMA)+1 Executive summary — the one-minute version What PRAC found (evidence & conclusions) Key regulatory changes and public health measures Clinical and public-health implications (who should worry and what to do) Impact on manufacturers — regulatory & operational checklist Manufacturers (brand and […]
EMA’s Update on Azithromycin Use — May 23, 2025
Key Regulatory Shift The European Medicines Agency’s (EMA) CHMP recommended updating the approved uses of azithromycin (oral and IV) to combat rising antimicrobial resistance (AMR)—particularly given its designation in WHO’s Watch category, which flags antibiotics at higher risk of driving resistance. (turn0search0) What’s Changed? Refined and Harmonized Indications Approvals have been narrowed and standardized, covering […]
Short Note on Regulation (EU) No 536/2014 on Clinical Trials
Regulation (EU) No 536/2014, enacted by the European Parliament and the Council on April 16, 2014, provides a comprehensive framework for the conduct of clinical trials on medicinal products for human use within the EU. It aims to ensure the protection of participants’ rights, safety, and well-being while facilitating the efficient and ethical conduct of […]
The EU Decentralised Clinical Trials Project: Revolutionizing Clinical Research
Background The landscape of clinical trials in the European Union (EU) is evolving, driven by the need for innovative trial designs and methodologies that address both emerging opportunities and inherent challenges. The EU Decentralised Clinical Trials (DCT) project is a pioneering initiative aimed at transforming the traditional clinical trial framework to enhance accessibility and convenience […]